Log In
Print
BCIQ
Print
Print this Print this
 

IV solithromycin (CEM-101) (formerly OPT-1068)

  Manage Alerts
Collapse Summary General Information
Company Cubist Pharmaceuticals Inc.
DescriptionIV formulation of a fluoroketolide/macrolide antibiotic
Molecular Target Ribosomal 50S subunit
Mechanism of ActionRibosomal 50S subunit inhibitor
Therapeutic ModalityMacrocycle
Latest Stage of DevelopmentPhase III
Standard IndicationPneumonia
Indication DetailsTreat moderate to severe community-acquired bacterial pneumonia (CABP)
Regulatory Designation

Partner

Cempra Inc.; Toyama Chemical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today